Eva Maria Dahlén,Karin Elisabeth Barchan,Patrick Thomas Höjman,Cecilia Ann-Christin Malmborg Hager,Marie Asa Ingegerd Karlsson,Mats Peter Anderson,Björn Ulrik Walse
申请号：
US12598140
公开号：
US08303945B2
申请日:
2008.05.01
申请国别(地区):
US
年份:
2012
代理人:
摘要：
The invention provides an isolated polypeptide comprising a variant amino acid sequence of SEQ ID NO: 1, or a fusion or derivative of said polypeptide, or a fusion of a said derivative thereof, wherein the polypeptide, fusion or derivative retains a biological activity of wild type IL-IRa. In one embodiment, the isolated polypeptide, fusion or derivative is or comprises a polypeptide variant of amino acid sequence SEQ ID NO: 1 comprising or consisting of substitutions at one or more of the following amino acid mutations of SEQ ID NO: 1: Q29K, P38Y, P38R, L42W, D47N, E52R, H54R, E90Y, Q129L, Q129N, M136N, M136D and Q149K. Also provided are pharmaceutical compositions of the above polypeptide, fusion or derivative, as well as uses of the same for treating a disease or condition capable of being treated by an agent which inhibits the function of IL-1 receptors.
